


Declaration of Interests Register


TA Committee C Publication Date: 30/09/2020

Topic: Pembrolizumab with axitinib for untreated advanced renal cell carcinoma [ID1426]

Name	Role with NICE	Type of interest	Description of interest	Relevant dates		es	Comments
				Interest arose	Interest declared	Interest ceased	
Richard Nicholas	TA Committee C Member	Indirect - financial	Richard Nicholas provided work for a comparator company, Novartis Pharmaceuticals, in an unrelated disease area	Not specified	Jan 2020	Not specified	It was agreed that this declaration would not prevent Richard Nicholas from participating in this section of the meeting.
Prithwiraj Das	TA Committee C Member	Indirect - financial	Prithwiraj Das works in Market Access at Boehringer Ingelheim on products in an unrelated disease area	Not specified	Jan 2020 & July 2020	Not specified	It was agreed that this declaration would not prevent Prithwiraj Das from participating in this section of the meeting
Balaji Venugopal	Clinical expert	Direct - financial	Balaji Venugopal is a member of an advisory board for Bristol Myers & Squibb Pharmaceuticals, EUSA Pharma, Merck and Merck Sharp & Dohme.	Not specified	Jan 2020 & July 2020	Not specified	It was agreed that these declarations would not prevent Balaji Venugopal from participating in this section of the meeting
			He was a principal investigator in clinical trials sponsored by Merck Sharp & Dohme, Ipsen and Pfizer.				



Tom Waddell	Clinical expert	Direct - financial	Tom Waddell was a Clinical Advisor to the Evidence Review Group, Liverpool Reviews & Implementation Group. He provided advice on reviewing a company submission based on the combination of Avelumab and Axitinib. He received a research grant and consultancy fee provided by Merk Sharp & Dohme.	Not specified	Jan 2020 & July 2020	Not specified	It was agreed that these declarations would not prevent Tom Waddell from participating in this section of the meeting
Susanna Smith	Patient expert	Direct - financial	Susanna Smith works for Kidney Cancer UK which received funding from Merck Sharp & Dohme, Bristol Myers-Squibb Pharmaceuticals, Ipsen, EUSA Pharmaceuticals and Biocompatibles.	Not specified	Jan 2020 & July 2020	Not specified	It was agreed that this declaration would not prevent Susanna Smith from participating in this section of the meeting.
			She has been involved in supporting recent clinical trial studies using kidney cancer drugs.				
			She received nurse advisory consultancy fees from Merck Sharp & Dohme and Ipsen.				
Michael Lee	Patient expert	Direct – non- financial	Michael Lee participated as a patient in clinical trial studies	Not specified	Jan 2020 &	Not specified	It was agreed that this declaration would not prevent



	of Pembrolizumab with axitinib.	July 2020	Michael Lee from participating in this section of the meeting
			9